Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Boehringer Ingelheim

Status: Active, not recruiting

Conditions: Kidney Disease, Chronic

Treatments: Drug: JARDIANCE®

Study type: Observational

Funder types: Industry

Identifiers

NCT06527846

1245-0340

Details and patient eligibility

About

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.

Enrollment: 1,027 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to the current Japanese package insert and who provided written informed consent prior to enrolment in this study.
• Patients who have never been treated with JARDIANCE® Tablets (including treatment for Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) before enrolment.

Exclusion criteria

• None

Trial design

1,027 participants in 1 patient group

Patients with chronic kidney disease (CKD)

Treatment:

Drug: JARDIANCE®